You are here

Innovent

Lilly's next-gen obesity drug brings Innovent a phase 3 win in diabetes

Fierce Biotech

Thu, 05/9/24 - 11:48 am

type 2 diabetes

Innovent's anti-VEGF drug matches Eylea in phase 2 eye disease trial

Fierce Biotech

Tue, 03/19/24 - 11:21 am

neovascular age-related macular degeneration

Next-gen Lilly obesity drug slashes weight in Innovent study—but is it enough to rival Mounjaro?

Fierce Biotech

Fri, 05/12/23 - 11:41 am

clinical trials

AACR 2023 – Moderna's immunotherapeutic splash

EP Vantage

Wed, 03/22/23 - 10:03 am

Moderna Therapeutics

Relay Therapeutics

Vivace Therapeutics

Pursuing AbbVie and J&J, Innovent hits primary endpoint in phase 2 psoriasis trial

Fierce Biotech

Wed, 08/10/22 - 10:49 am

monoclonal antibodies

clinical trials

Looking east, Sanofi pens 'pioneering' cancer drug partnership with China's Innovent

Fierce Biotech

Fri, 08/5/22 - 10:38 am

Innovent & Eli Lilly's Type 2 Diabetes Drug Lowers HbA1c, Scores Early Win

BioSpace

Tue, 07/19/22 - 10:26 am

type 2 diabetes

clinical trials

Innovent catching up with Lilly, Novo Nordisk thanks to phase 2 obesity data

Fierce Biotech

Wed, 06/8/22 - 10:34 am

clinical trials

What now for low-cost PD-(L)1 competition?

EP Vantage

Fri, 03/18/22 - 10:25 am

Eli Lilly, Innovent's PD-1 in troubled waters as FDA review, oncology chief's comments portend likely rejection

Fierce Pharma

Wed, 02/9/22 - 10:56 am

PD-1 inhibitors

Good news for Lilly as sintilimab hits the spot in lung cancer again

Pharmaforum

Tue, 10/19/21 - 10:47 am

non-squamous non-small cell lung cancer

non-small cell lung cancer

FDA review of Lilly/Innovent’s sintilimab paves way for cut-price immunotherapy option

Pharmaforum

Wed, 05/19/21 - 10:26 am

Racing ahead of Merck and Innovent, Junshi declares PhIII success on cancer that won them 'breakthrough' status

Endpoints

Tue, 09/29/20 - 11:51 am

Junshi Biosciences

nasopharyngeal carcinoma